CommercialCoverageMedium impact
08.00.70e, Enzyme Replacement Therapy for Mucopolysaccharidosis (e.g., Aldurazyme®, Elaprase®, Vimizim®, Naglazyme®, Mepsevii™, etc.)
Independence Blue Cross·Endocrinology, Pediatrics, Family Medicine +1 more·Pharmacy
Effective date
Nov 26, 2025
We identified it
Jun 19, 2026
Summary
This is a reissue of the Enzyme Replacement Therapy policy for Mucopolysaccharidosis covering drugs like Aldurazyme, Elaprase, Vimizim, Naglazyme, and Mepsevii. The policy has been updated but specific changes are not detailed in the summary provided.
Action Required
By November 26, 2025: Billing team should review the complete updated policy at the provided URL to understand any changes to coverage criteria, prior authorization requirements, or billing procedures for enzyme replacement therapy drugs used to treat Mucopolysaccharidosis. Update any relevant billing protocols based on the full policy details.